This is the flow from muscle-health screening and assessment to personalized exercise prescription. Internally, a five-stage CEP-Pipeline (Controlled Exercise Prescription Pipeline) implements this flow, with each stage grounded in related research and IP.
KINAI researches and validates exercise prescription, rule-guided decision, and muscle-health pre-screening technologies. Each is developed on the basis of related research findings and our IP portfolio.
Verifies whether safe prescriptions remain consistent across identical inputs, and whether the prescription pathway is properly controlled based on physical function level and individual imbalances.
Measures AI decision errors in rule-intensive domains such as anti-doping, where incorrect judgments can have significant consequences, and investigates decision structures that incorporate explicit rules and safety constraints. Related research was submitted to a KADA (Korea Anti-Doping Agency) competition.
Pre-screens individuals who may need additional muscle-health assessment using routine health-checkup data and connects them to follow-up assessment. Temporal validation was conducted using an independent 2024 dataset.